Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorapaxar in Acute Coronary Syndrome (TRA•CER)
NCT00527943Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2007
- Primary completion
- Jul 2011
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of vorapaxar in acute coronary syndrome (ACS), sponsored by Merck & Co.. Started Dec 2007; status: terminated.
02
Drugs
vorapaxar
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT00527943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00527943.